-
Mashup Score: 13Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation - 6 month(s) ago
Coeliac disease (CD) is a chronic inflammatory and autoimmune disorder, primarily affecting the small intestine, developed in genetically susceptible individuals upon gluten ingestion. The only effective treatment so far is a lifelong, strict gluten-free diet. However, difficulties to follow dietary compliance can lead to complications, highlighting the unmet need for adjuvant therapies. Recently in Gut, we described a novel m6A-XPO1-NFκB pathway that is activated in patients with CD. Specifically, YTHDF1 m6A reader was found to selectively bind the 5’ UTR of XPO1 mRNA and induce its translation, increasing XPO1-mediated inflammation in intestinal cells both in vitro and in vivo .1 These findings opened the door to new therapeutic approaches directed to m6A machinery proteins, already in use for the treatment of other disorders.2 Interestingly, novel studies have described salvianolic acid (SAC) as a selective inhibitor of YTHDF1, which can rescue Fragile X syndrome linked defects in n
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 21Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis - 6 month(s) ago
Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 pat
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 12Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation - 6 month(s) ago
Coeliac disease (CD) is a chronic inflammatory and autoimmune disorder, primarily affecting the small intestine, developed in genetically susceptible individuals upon gluten ingestion. The only effective treatment so far is a lifelong, strict gluten-free diet. However, difficulties to follow dietary compliance can lead to complications, highlighting the unmet need for adjuvant therapies. Recently in Gut, we described a novel m6A-XPO1-NFκB pathway that is activated in patients with CD. Specifically, YTHDF1 m6A reader was found to selectively bind the 5’ UTR of XPO1 mRNA and induce its translation, increasing XPO1-mediated inflammation in intestinal cells both in vitro and in vivo .1 These findings opened the door to new therapeutic approaches directed to m6A machinery proteins, already in use for the treatment of other disorders.2 Interestingly, novel studies have described salvianolic acid (SAC) as a selective inhibitor of YTHDF1, which can rescue Fragile X syndrome linked defects in n
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5
Objective Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option. Design A algorithm was developed to reclassify GC into immune inflamed, excluded and desert subtypes. Bioinformatics, human and mouse GC cell lines, syngeneic murine gastric tumour model, and CTLA4 blockade were used to investigate the immunotherapeutic effects by restricting receptor tyrosine kinase (RTK) signalling in immune desert (ICB-resistant) type GC. Results Our algorithm restratified subtypes of human GC in public databases and showed that immune desert-type and excluded-type tumours are ICB-resistant compared with immune-inflamed GC. Moreover, epithelial-mesenchymal transition (EMT) signalling was highly enriched in
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by Cao et al entitled "Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling" via https://t.co/t7hvMLG1wX @DrJashDatta https://t.co/W4c32nViK6
-
-
Mashup Score: 12Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation - 6 month(s) ago
Coeliac disease (CD) is a chronic inflammatory and autoimmune disorder, primarily affecting the small intestine, developed in genetically susceptible individuals upon gluten ingestion. The only effective treatment so far is a lifelong, strict gluten-free diet. However, difficulties to follow dietary compliance can lead to complications, highlighting the unmet need for adjuvant therapies. Recently in Gut, we described a novel m6A-XPO1-NFκB pathway that is activated in patients with CD. Specifically, YTHDF1 m6A reader was found to selectively bind the 5’ UTR of XPO1 mRNA and induce its translation, increasing XPO1-mediated inflammation in intestinal cells both in vitro and in vivo .1 These findings opened the door to new therapeutic approaches directed to m6A machinery proteins, already in use for the treatment of other disorders.2 Interestingly, novel studies have described salvianolic acid (SAC) as a selective inhibitor of YTHDF1, which can rescue Fragile X syndrome linked defects in n
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 21Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis - 6 month(s) ago
Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 pat
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5
Objective Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option. Design A algorithm was developed to reclassify GC into immune inflamed, excluded and desert subtypes. Bioinformatics, human and mouse GC cell lines, syngeneic murine gastric tumour model, and CTLA4 blockade were used to investigate the immunotherapeutic effects by restricting receptor tyrosine kinase (RTK) signalling in immune desert (ICB-resistant) type GC. Results Our algorithm restratified subtypes of human GC in public databases and showed that immune desert-type and excluded-type tumours are ICB-resistant compared with immune-inflamed GC. Moreover, epithelial-mesenchymal transition (EMT) signalling was highly enriched in
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by Cao et al entitled "Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling" via https://t.co/t7hvMLG1wX @DrJashDatta https://t.co/W4c32nViK6
-
-
Mashup Score: 21Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis - 6 month(s) ago
Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 pat
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5
Objective Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option. Design A algorithm was developed to reclassify GC into immune inflamed, excluded and desert subtypes. Bioinformatics, human and mouse GC cell lines, syngeneic murine gastric tumour model, and CTLA4 blockade were used to investigate the immunotherapeutic effects by restricting receptor tyrosine kinase (RTK) signalling in immune desert (ICB-resistant) type GC. Results Our algorithm restratified subtypes of human GC in public databases and showed that immune desert-type and excluded-type tumours are ICB-resistant compared with immune-inflamed GC. Moreover, epithelial-mesenchymal transition (EMT) signalling was highly enriched in
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet-
#GUTImage from the paper by Cao et al entitled "Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling" via https://t.co/t7hvMLG1wX @DrJashDatta https://t.co/W4c32nViK6
-
-
Mashup Score: 21Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis - 6 month(s) ago
Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 pat
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
#GUTImage on the paper by @AinaCastellanos et al entitled "Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation" via https://t.co/cVqsB33Rvk @FunImmune @ane_ola @HRMrqz @Ikerbasque @upvehu @biocrucesHRI https://t.co/kTfOn1ooxC